Australia's largest stock trading and investment forum Australia's #1 stock forum

PBT

0.00%

0.0¢ prana biotechnology limited

On 1st of Dec 2016 the share price of Prana in NY was US$ 1.63...

First 20 Last

Share
Profile

Follow
pivalde

1,078 Posts.

160

30/11/18

18:02

Post #: 36710127
Share

Originally posted by billy2803 ↑

Originally posted by pivalde
2y ago we had a very similar situation, market value going down and down just before the year ended. Then in the new year there was gradual improvement. It looked as people wanted to sell because of tax purposes. The selling today may be caused because other reasons but while many other shares are on much higher levels it is easy to balance the losses in Prana.

2 y ago IMO Prana did not have very clear path forward. Prana told to do some short clinical studies with PBT2 but in the end nothing was done. Today IMO things are more clear. PBT434 has IMO better future when comparing with PBT2 2 years ago ( after Imagine study) and it can be very successful according the preclinical studies and the beginning of the phase 1. At least the plans are clear: orphan drug application and MSA phase 2 study after phase 1.

2y ago the understanding of the pathogenesis of both PD and AD were not so clear as they are today. Almost nobody talked about mitochondria or energy problems of the brain. According the preclinical results there is clear evidence that PBT434 has possibilities to help these patients (???). But nothing is clear before first phase 1 and then phase 2 results and of course this is the main reason why the stock price has been going down for months.

The "best" in the future of PBT434 IMO is that it seems to help the energy problem of all organs because it helps mitochondria by eliminating gradually accumulating iron which is hampering energy production and also causing mitochondrial fission and so ROS production. So possibly PBT434 can help many other mitochondrion diseases which earlier were not at all considered to be mitochondrion diseases: glaucoma, macula degeneration, osteoporosis, senile muscle atrophy, various heart disease, brain trauma etc. Critically ill people is the latest point on my list. Think about when do your cells need more energy than when they are just about to die ( iron hampering mitochondria).
Clearly the market doesn't agree. 2 years ago, shareholder wealth was almost double to what it is now. These are facts, "pivalde".

Apologies for sounding rude, but your post above is hype. I think general investors are/were too burnt by the hype of the Imagine trial (remember all of Tanzi's tweets in the lead up to it?) to believe it again this time around, and would rather rely on facts coming out of Prana's HQ before it gets sucked in again.

So until we see more solid evidence of their success/potential, I take any analysis posted on here with a grain of salt (to be honest, I rarely read it). And it's clear the market shares the same sentiment as I do.

Expand

On 1st of Dec 2016 the share price of Prana in NY was US$ 1.63 and yesterday it was 1.62. If you calculate that the value of US$ is up during this 2 y time so the value almost in any currency is still some higher than 2 y ago. These are the facts how I calculate. Billy, How do you look and calculate these values ?

PBT Price at posting: 3.7¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

AXP

Tambourah chases gold veins and mineralisation extension with drilling

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

There are more pages in this discussion • 40 more messages in this thread...

First 20 Last

Add PBT (ASX) to my watchlist

On 1st of Dec 2016 the share price of Prana in NY was US$ 1.63...

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Tambourah chases gold veins and mineralisation extension with drilling

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Featured News